Property Name |
Property Value |
Unit |
Raw Value |
Raw Unit |
Annotation |
Factor |
Reference |
C Max |
39000.0 |
ng/ml |
39±17 |
mcg/ml |
adults; ovarian cancer; |
|
The Pharmacological Basis of Therapeutics |
T Max |
0.50 |
h |
0.5 |
h |
adults; ovarian cancer; |
|
The Pharmacological Basis of Therapeutics |
Clearance |
4.4 |
L/h |
4.4 |
L/h |
Total clearance; intravenous injection, IV; |
|
DRUGBANK |
Clearance |
0.0900 |
L/h/kg |
1.5±0.3 |
ml/min/kg |
|
RD, renal impairment, Renal disease,including uremia ↓ ; |
The Pharmacological Basis of Therapeutics |
Clearance |
0.0900 |
L/h/kg |
1.5 |
ml/min/kg |
intravenous injection, IV; human, homo sapiens; |
|
Human Intravenous Pharmacokinetic Dataset |
Volume of Distribution |
16.0 |
L |
16.0 |
L |
Apparent volume of distribution; intravenous injection, IV; |
|
DRUGBANK |
Volume of Distribution |
0.24 |
L/kg |
0.24±0.03 |
L/kg |
|
|
The Pharmacological Basis of Therapeutics |
Volume of Distribution |
0.26 |
L/kg |
0.26 |
L/kg |
intravenous injection, IV; human, homo sapiens; |
|
Human Intravenous Pharmacokinetic Dataset |
Half-life |
1.6 |
h |
1.1-2 |
h |
distribution half-life; |
|
DRUGBANK |
Half-life |
4.3 |
h |
2.6-5.9 |
h |
elimination half-life; |
|
DRUGBANK |
Half-life |
2.0 |
h |
2±0.2 |
h |
|
RD, renal impairment, Renal disease,including uremia ↑ ; |
The Pharmacological Basis of Therapeutics |
Half-life |
2.0 |
h |
2 |
h |
intravenous injection, IV; human, homo sapiens; |
|
Human Intravenous Pharmacokinetic Dataset |
Toxicity LD50 |
343.0 |
mg/kg |
343.0 |
mg/kg |
PO, oral; Rattus, Rat; |
|
DRUGBANK |
Toxicity LD50 |
72.0 |
mg/kg |
72.0 |
mg/kg |
subcutaneous injection, SC; Rattus, Rat; |
|
DRUGBANK |
Toxicity LD50 |
118.0 |
mg/kg |
118.0 |
mg/kg |
Intraperitoneal, IP; mouse; |
|
DRUGBANK |
Eliminate Route |
77.0 |
% |
77±5 |
% |
Urinary excretion; Unchanged drug; |
|
The Pharmacological Basis of Therapeutics |
Protein Binding |
0 |
% |
0 |
% |
|
|
The Pharmacological Basis of Therapeutics |